A Look At Immunome (IMNM) Valuation After New Barclays Overweight Coverage

Simply Wall St.

May 31

Immunome (IMNM) drew fresh investor attention after Barclays began covering the stock with an Overweight rating, highlighting its antibody drug conjugate platform and broader oncology pipeline within ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2639600128"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2639600128\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2639600128?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-05-31 15:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639600128","market":"nz","top_or_hot":-1,"title":"A Look At Immunome (IMNM) Valuation After New Barclays Overweight Coverage","media":"Simply Wall St.","content":"<div>\n<p>Immunome (IMNM) drew fresh investor attention after Barclays began covering the stock with an Overweight rating, highlighting its antibody drug conjugate platform and broader oncology pipeline within ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imnm/immunome/news/a-look-at-immunome-imnm-valuation-after-new-barclays-overwei\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Immunome (IMNM) Valuation After New Barclays Overweight Coverage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Immunome (IMNM) Valuation After New Barclays Overweight Coverage\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-31 15:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imnm/immunome/news/a-look-at-immunome-imnm-valuation-after-new-barclays-overwei><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immunome (IMNM) drew fresh investor attention after Barclays began covering the stock with an Overweight rating, highlighting its antibody drug conjugate platform and broader oncology pipeline within ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imnm/immunome/news/a-look-at-immunome-imnm-valuation-after-new-barclays-overwei\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMNM","symbol_name":"Immunome Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imnm/immunome/news/a-look-at-immunome-imnm-valuation-after-new-barclays-overwei","article_id":"2639600128","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imnm/immunome/news/a-look-at-immunome-imnm-valuation-after-new-barclays-overwei","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2639600128","pubTimestamp":1780211265,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Immunome (IMNM) drew fresh investor attention after Barclays began covering the stock with an Overweight rating, highlighting its antibody drug conjugate platform and broader oncology pipeline within the small and mid cap biotech space.\nSee our latest analysis for Immunome.\nAt a share price of US$21.83, Immunome has seen mixed recent share price returns, with modest gains year to date alongside a very large 1 year total shareholder return and a multi year total shareholder return above 3x...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"IMNM":"Immunome Inc."},"translate_title":"Barclays跑赢大盘新报道后Immunome(IMNM)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMNM":1.5},"content_text":"Immunome (IMNM) drew fresh investor attention after Barclays began covering the stock with an Overweight rating, highlighting its antibody drug conjugate platform and broader oncology pipeline within the small and mid cap biotech space. See our latest analysis for Immunome. At a share price of US$21.83, Immunome has seen mixed recent share price returns, with modest gains year to date alongside a very large 1 year total shareholder return and a multi year total shareholder return above 3x. This suggests that momentum has broadly been building around its oncology pipeline and recent conference and coverage announcements. If you are looking beyond Immunome and want to see what else is moving in cancer focused technology, take a look at our screener of 39 healthcare AI stocks With the stock trading at a sizeable discount to the average analyst price target and an intrinsic value estimate suggesting further upside, the key question is whether Immunome is still mispriced or if the market is already assuming strong future growth. AdvertisementPrice to Book of 4.2x: Is it justified? On a P/B of 4.2x, Immunome trades at a higher valuation than the broader US biotech industry average of 2.6x, yet below its closer peer group on 8.4x. The P/B ratio compares the stock price with the accounting value of net assets. This can be a common yardstick for early stage or loss making biotechs where earnings are not yet a meaningful guide. A higher P/B often reflects the market assigning more value to a company’s pipeline, intellectual property or future revenue potential than its current balance sheet would suggest. For Immunome, the stock is more expensive than the wider US biotech industry on this metric. This points to stronger expectations being priced in than for the average company. However, the P/B is lower than the peer average. This suggests that, relative to a closer group of comparable biotechs, the market is assigning a more moderate premium to Immunome’s assets and oncology programs. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 4.2x (ABOUT RIGHT) However, recent share price pullbacks over 1 day, 30 days and 90 days, together with ongoing net losses of US$224.593 million, could quickly test that optimism. Find out about the key risks to this Immunome narrative. Another View: What Does The SWS DCF Model Say? While the P/B of 4.2x sits above the broader biotech average, the SWS DCF model points in a very different direction. At a share price of $21.83, Immunome is trading about 85.9% below an estimated future cash flow value of $154.39. That gap raises a clear question: is the market being too cautious about long term cash generation? Look into how the SWS DCF model arrives at its fair value. IMNM Discounted Cash Flow as at May 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Immunome for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Mixed signals on valuation and sentiment can be hard to interpret, so it makes sense to review the data yourself and decide how comfortable you are with the balance between potential and risk. To help you weigh both sides in one place, take a closer look at the 3 key rewards and 4 important warning signs. Looking for more investment ideas? If Immunome has caught your eye, do not stop here. Use the tools available to spot other opportunities before they move beyond your comfort zone.  Target potential upside by scanning for companies that look mispriced on fundamentals with the help of 46 high quality undervalued stocks. Protect your capital by focusing on companies with healthier finances using the solid balance sheet and fundamentals stocks screener (46 results). Get ahead of the crowd by spotting underfollowed opportunities through the screener containing 22 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}